Paragon Bioservices Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Paragon Bioservices's estimated annual revenue is currently $51.2M per year.
- Paragon Bioservices received $5.0M in venture funding in August 2018.
- Paragon Bioservices's estimated revenue per employee is $155,000
- Paragon Bioservices's total funding is $22.9M.
- Paragon Bioservices has 330 Employees.
- Paragon Bioservices grew their employee count by -5% last year.
- Paragon Bioservices currently has 89 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Pricing|
|American Gene T...||$4.7M||30||N/A||N/A||N/A|
What Is Paragon Bioservices?
Paragon Bioservices is an industry-leading, private-equity backed contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of cutting-edge biopharmaceuticals. Paragon's aim is to build strong client partnerships with the world's best biotech and pharma companies, focusing on transformative technologies, including gene therapies (AAV), next-generation vaccines, oncology immunotherapies (oncolytic viruses and CAR-T cell therapies), therapeutic protein, and other complex biologics.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Michele Dumas||Manager, Sales Administration|
|Mark Adams||Vice President Of Project Management|
|Ryan Behles||Sr. Project Manager||Email Available|
|Lauren Floccare||Senior Manager, Upstream Manufacturing||Email Available|
|Hope Mozzani||Manager, Validation at Eisai, Inc|
|Bala Medicherla||Bio-analytics Manager||Email Available|
|George Kuck||Director Of Manufacturing Operations||Email Available|
|Warren Wilson||Facilities/ Manager|
|Nikolce Gjoreski||Manager, Facilities And Engineering||Email Available|
Paragon Bioservices News
Just this year, Catalent bought out California-based Paragon Bioservices? and Thermo Fisher Scientific acquired Brammer Bio?, located in ...
By April of 2019, Catalent had agreed to a $1.2 billion acquisition of gene therapy developer Paragon Bioservices. And most recently, the ...
Why Paragon Bioservices' $1.2B acquisition deal matters to Baltimore ... it had agreed to acquire Paragon Bioservices in a $1.2 billion deal.
Paragon Bioservices Funding
Paragon Bioservices Executive Hires
|2011-07-21||Vadim Klyushnichenko||VP Preclinical Services/Process Develo||Article|
|2014-10-29||Peter L. Buzy||COO||Article|
|2015-10-01||Carolyn Phillips||VP Quality||Article|
|2015-10-30||Kevin Sly||SVP Marketing & Commercial Strategy||Article|
|2016-03-08||William Thomas Jr||Chief Technology Officer||Article|
|2016-08-11||Mark Adams||VP Project Management||Article|
|2016-09-13||Peter Buzy||President/Chief Executive Officer||Article|
|2016-11-21||Ruby Hofmann||VP Human Resources/Organizational Development||Article|
|2016-11-23||John Conner||SVP GMP Manufacturing||Article|
|2017-07-21||Deborah Wild||vp Quality/Regulatory Affairs||Article|
|2018-01-26||Philip Wills||Chief Commercial Officer||Article|
|2018-08-09||Deborah Wild||sVice President of Quality and Regulatory Affairs||Article|
|2019-03-22||Thomas VanCott||Chief Technology & Strategy Officer||Article|